Illumina TruSeq Bovine Parentage Sequencing Panel

Jul 27, 2016

Illumina has launched its TruSeq Bovine Parentage Sequencing panel. The new kit tests for 266 SNP-based markers, including 200 markers recommended by the International Society for Animal Genetics for establishing parentage in cattle, and 66 additional SNPs associated with economically relevant traits. The test also allows laboratories to run 96 samples together, and quickly deliver a report in 1.5 days.

More Like This

Feb 22, 2018

Tempus xE Whole-Exome Tumor Sequencing

Personalized cancer technology company Tempus has introduced Tempus xE, a whole-exome sequencing panel that analyzes tumor DNA alongside a normal sample and a whole-RNA transcriptome. The new CLIA/CAP-validated assay gives researchers and clinicians a broad view of potential tumor mutations and treatment pathways, Tempus said. 

Feb 21, 2018

Optra Health OptraGuru 'Digital Genetic Assistant'

Optra Health has introduced OptraGuru, an Amazon Alexa-compatible "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data. Meant to provide context to consumer genetic tests like those from Ancestry.com and 23andMe, OptraGuru puts the Alexa personal digital assistant on the front end of Optra Health's iPhronesis machine-learning platform to help patients, genetic counselors, and bioinformaticians make sense of genetic test results in a conversational manner.

Feb 15, 2018

Twist Bioscience Twist Human Core Exome Kit

Twist Bioscience has commercially launched its Twist Human Core Exome Kit, a comprehensive library preparation and target enrichment kit. It is based on the firm's DNA synthesis technology and includes all the tools needed for library construction, target capture, and enrichment to prepare a sample for sequencing, the firm said. Twist said that as part of the kit, it will offer an option to add IntegraGen’s cloud-based platforms, Mercury and Sirius, for analysis of germline or cancer samples. In addition to the exome kit, Twist also said it has launched a custom panels offering tailored to individual customer requests.

Feb 15, 2018

Omega Bio-Tek Mag-Bind Blood DNA HIV Kit

Omega Bio-Tek announced the launch of its Mag-Bind Blood DNA HV kit, which extracts genomic DNA from large volume blood samples in a fully automated solution. The firm's kit combines extraction chemistry on the Hamilton Microlab STAR liquid platform to provide expedited results for applications including biorepositories, genomics research, and pharmacogenetics that require massive amounts of DNA extraction. The firm believes that the kit will allow researchers to process up to twenty-four 10 milliliters blood samples in 2.5 hours without compromising DNA yield and quality. Omega Bio-tek business director Travis Butts noted that the workflow can perform from volumes as small as 250 microliters to 10 milliliters without additional expensive accessories on the Hamilton platform.

Feb 13, 2018

DNAnexus Clinical Trial Solution

DNAnexus has released Clinical Trial Solution, a cloud-based system that bundles secondary analysis, interpretation, and translational informatics for using next-generation sequencing data in clinical trials. DNAnexus said that its GxP-compliant CTS combines omic information with data from clinical trials to help reduce the time and expense of trial design and drug development. 

Feb 13, 2018

SeraCare Seraseq Breast CNV; Lung and Brain CNV Mix

SeraCare Life Sciences launched the Seraseq Breast CNV and Seraseq Lung and Brain CNV Mix, reference materials for analyzing copy number variation. Both have been built with biosynthetic technology that can be easily scalable to incorporate new CNVs over time, and were developed so that clinical labs conducting NGS-based tumor profiling for cancer can better understand and characterize their assays, SeraCare said. They were precisely quantified using highly sensitive digital PCR assays to analyze amplification of EGFR, MET, FGFR3, MYC, ERBB2, and MYCN genes at +3, +6, and +12 copies against a single well-characterized genomic background, the company said.

Feb 12, 2018

Bionano Genomics Direct Label and Stain

Bionano Genomics announced today the global launch of its Direct Label and Stain (DLS), a new chemistry for sequencing motif labeling. The kit is a non-destructive labeing chemistry that will improve the firm's Saphyr genome mapping system. Bionano claims that the DLS will also improve sensitivity for all structural variant calls, yielding detection of heterozygous insertions and deletions as small as 500 bp. The DLS kits will allow high-volume users to map a human genome for $500.  

Feb 09, 2018

Sema4 Natalis

Sema4 has launched Natalis, a supplemental newborn screening test designed to detect 193 childhood-onset diseases or disorders. In the US, newborns are typically screened for 34 health conditions on the recommended uniform screening panel, but the conditions vary by state and represent only a fraction of the genetic diseases that can manifest in a child's first decade, Sema4 noted. As a supplemental test, Natalis screens for more than five times the number of genetic diseases than a state's standard hospital test, the company said. Every Sema4 Natalis order also includes a pharmacogenetic analysis of how a baby is likely to respond to 38 medications commonly prescribed at an early age. The test uses DNA sequencing analysis, and sample collection can be performed at home with a cheek swab, the company said.

Feb 08, 2018

NuGen Technologies Celero DNA-Seq

NuGen Technologies has launched Celero DNA-Seq, a library prep system for Illumina sequencers. The system includes library quantitation called NuQuant, which directly measures the molar concentration in a library, eliminating the need for serially diluting libraries and estimating library size, according to the company. It also includes master mixes that include all necessary components, and is amenable to automation.

The Celero DNA-Seq system will be available with Unique Dual Indexes as well as Metaplex barcode options to increase multiplexing.  

Feb 08, 2018

Cofactor Genomics Paragon

Cofactor Genomics has launched Paragon, a cancer type-agnostic solid tumor immune-profiling assay that uses a proprietary database of immune reference signatures to interrogate immune activity associated with disease or therapy response. For example, the assay can differentiate cells such as M1 and M2 macrophages and can report cancer-specific expression signals from genes including PD-1, PD-L1, and CTLA4. The assay requires only two FFPE tissue sections for analysis and can accommodate any solid tumor specimen, with expression databases pre-built for more than 25 different cancer types, Cofactor said.
Feb 07, 2018

Quantabio Q Thermal Cycler

Quantabio has launched Q, a portable thermal cycler that weighs 4.5 pounds and processes up to 48 samples per run. The instrument can detect two-fold expression level differences and yields results in as little as 25 minutes without any calibration. Up to 10 instruments can be connected with Bluetooth, enabling processing of up to 480 samples in a single data set.

Feb 07, 2018

Mission Bio Tapestri Custom Panels

Mission Bio has launched Tapestri Custom Panels to enable researchers to conduct single-cell DNA analysis for genetic mutation research. The panels have a throughput of 10,000 cells per run and are compatible with a wide range of samples including cell lines, PBMCs, bone marrow, and fresh frozen solid tissue nuclei, enabling researchers examining a range of complex diseases to fully resolve clonal heterogeneity and mutational co-occurrence. Mission Bio's Tapestri platform debuted in October 2017 and includes an instrument, consumables, and software for single-cell genomics analysis.

Feb 06, 2018

Personalis ImmunogenomicsID and NeoantigenID

Personalis has launched ImmunogenomicsID, which combines DNA and RNA sequencing data to generate an immunogenomic profile of a tumor and its microenvironment. The product is designed to help identify biomarkers and signatures that can impact patient response to cancer immunotherapies. It is a new component and extension of the company's existing ACE ImmunoID Platform, which combines genome-scale sequencing with data analytics for broad tumor immunogenomic characterization.  

The company also announced the latest release of NeoantigenID, a component of the ACE ImmunoID platform. ACE ImmunoID, which uses Personalis' patented ACE technology, combines augmented exome and transcriptome sequencing with analytics to enable broad tumor immunogenomic characterization. This newest release of NeoantigenID not only identifies candidate neoantigens derived from single nucleotide variants, but now also includes putative neoantigens derived from insertion and deletion mutations and gene fusions, for both MHC Class I and Class II, the company said. The new analytics integrate DNA and RNA sequencing data to calculate neoantigen load, expression of genes, and expression of variants, while incorporating phasing information to improve the accuracy of neoantigen prediction.

Feb 05, 2018

Thermo Fisher Scientific Axiom Microbiome Array

Thermo Fisher Scientific has launched the Applied Biosystems Axiom Microbiome Array for the detection of archaea, bacteria, fungi, protozoa, and viruses in human and other samples. The array was developed in collaboration with the Lawrence Livermore National Laboratory and carries sequences from almost 13,000 species. Prior to commercialization, the array was used in a pilot study of the UK Biobank. 

Feb 02, 2018

Lucence Diagnostics Plasma EGFR C797S Mutation Detection Assay

Lucence Diagnostics has launched its plasma EGFR C797S non-invasive mutation detection assay for clinical use in Southeast Asia. The assay is based on Lucence's proprietary Lumi-ARMS technology, and rapidly detects the presence of the EGFR C797S mutation which is linked with osimertinib resistance in EGFR-mutant non-small cell lung cancer. The assay can be used with blood and cerebrospinal fluid and features a sensitivity of up to 0.01 percent, the company said. The assay is also currently available as part of the Lucence LiquidTrack test offered through the company's reference laboratory in Singapore.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.

Feb
27
Sponsored by
Congenica

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep. 

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13
Sponsored by
Agilent

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03
Sponsored by
Dovetail Genomics

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.